Evidence map›Paper›PMID 39364684›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2024

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study.

Paulina B Lukow, Millie Lowther, Alexandra C Pike, Yumeya Yamamori, Alice V Chavanne, Siobhan Gormley, Jessica Aylward, Tayla McCloud, Talya Goble, Julia Rodriguez-Sanchez and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07074652 (The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07074652 nacompletednot on this map

The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

TypeinterventionalSponsorUCLH/UCL Joint Research OfficeRan2017 to 2022Enrolled145ConditionsAnxietyArmsEscitalopram, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paulina B LukowInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID 0000-0002-6796-9102
Millie LowtherInstitute of Cognitive Neuroscience, University College London, London, UK.
Alexandra C PikeInstitute of Cognitive Neuroscience, University College London, London, UK.
Yumeya YamamoriInstitute of Cognitive Neuroscience, University College London, London, UK.
Alice V ChavanneInstitute of Cognitive Neuroscience, University College London, London, UK.
Siobhan GormleyInstitute of Cognitive Neuroscience, University College London, London, UK.
Jessica AylwardInstitute of Cognitive Neuroscience, University College London, London, UK.
Tayla McCloudInstitute of Cognitive Neuroscience, University College London, London, UK.
Talya GobleInstitute of Cognitive Neuroscience, University College London, London, UK.
Julia Rodriguez-SanchezInstitute of Cognitive Neuroscience, University College London, London, UK.
Ella W TuominenInstitute of Cognitive Neuroscience, University College London, London, UK.
Sarah K BuehlerInstitute of Cognitive Neuroscience, University College London, London, UK.
Peter KirkInstitute of Cognitive Neuroscience, University College London, London, UK.
Oliver J RobinsonInstitute of Cognitive Neuroscience, University College London, London, UK.

Funding

Medical Research Council MR/K024280/1Wellcome Trust
6 · The paper itself

Abstract

backgroundSelective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood.

aimsTo investigate the neural correlates of subchronic antidepressant administration.

methodsWe investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before (

resultsCompared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration.

conclusionsTo date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may

Indexed as

AmygdalaEscitalopramMagnetic Resonance ImagingSelective Serotonin Reuptake InhibitorsAdultCitalopramDouble-Blind MethodFemaleHealthy VolunteersHumansMalePrefrontal CortexYoung AdultCitalopramEscitalopramSelective Serotonin Reuptake InhibitorsantidepressantsanxietyemotionescitalopramFunctional magnetic resonance imaging

Identifiers

PMID39364684
PMCPMC11531087

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.